Login to Your Account



Zealand Pharma Gets $11M Milestone from Deal

Abbott Acquires Action's AKI Compound for $110M in Cash

By Marie Powers
Staff Writer

Wednesday, May 9, 2012

Pharma giant Abbott plunked down $110 million in cash last week to acquire AP214, a first-in-class alpha-MSH peptide derivative designed to prevent acute kidney injury (AKI) during major cardiac surgery in patients at increased risk, from privately held Action Pharma A/S, of Aarhus, Denmark.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription